Platelet reactivity in response to loading dose of atorvastatin or rosuvastatin in patients with stable coronary disease before percutaneous coronary intervention: The STATIPLAT randomized study

Clinical Cardiology

Volumn 40, Issue 8, 2017, Pages 605-611

  Godino, Cosmo ^a   Pavon, Anna Giulia ^a   Mangieri, Antonio ^a   Salerno, Anna ^a   Cera, Michela ^a   Monello, Alberto ^a   Chieffo, Alaide ^a   Magni, Valeria ^a   Cappelletti, Alberto ^a   Margonato, Alberto ^a   Colombo, Antonio ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b EMO GVM CENTRO CUORE COLUMBUS   (Italy)

Author keywords

Atorvastatin; Clopidogrel; Platelet Reactivity; Rosuvastatin

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; ROSUVASTATIN; ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG RESPONSE; DUAL ANTIPLATELET THERAPY; FEMALE; HEMATOLOGICAL PROCEDURE; HUMAN; IMPEDANCE AGGREGOMETRY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; RANDOMIZED CONTROLLED TRIAL; SCREENING; STABLE ANGINA PECTORIS; BLOOD; BLOOD CLOTTING PARAMETERS; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG EFFECTS; DRUG INTERACTION; DRUG RESISTANCE; ITALY; MIDDLE AGED; PROSPECTIVE STUDY; THROMBOCYTE AGGREGATION; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANGINA, STABLE; ATORVASTATIN CALCIUM; CORONARY ARTERY DISEASE; DRUG INTERACTIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITALY; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; ROSUVASTATIN CALCIUM; TIME FACTORS; TREATMENT OUTCOME;

EID: 85018747271     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22709     Document Type: Article

References (22)

1. Sadowitz B, Maier KG, Gahtan V. Basic science review: Statin therapy—Part I: The pleiotropic effects of statins in cardiovascular disease. Vasc Endovascular Surg. 2010;44:241–251.
2. Szapary L, Horvath B, Marton Z, et al. Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia. CNS Drugs. 2004;18:165–172.
3. Undas A, Celińska-Löwenhoff M, Kaczor M, et al. New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost. 2004;91:1065–1077.
4. Pasceri V, Patti G, Nusca A, et al; ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) study. Circulation. 2004;110:674–678.
5. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49:1272–1278.
6. Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. J Am Coll Cardiol. 2009;54:558–565.
7. Piorkowski M, Weikert U, Schwimmbeck PL, et al. ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin. Thromb Haemost. 2004;92:614–620.
8. Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol. 2007;49:1035–1042.
9. Park Y, Jeong YH, Tantry US, et al. Accelerated platelet inhibition by switching from atorvastatin to a non–CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. Eur Heart J. 2012;33:2151–2162.
10. Pelliccia F, Rosano G, Marazzi G, et al. Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy—the PEARL randomized cross-over study. Eur J Pharmacol. 2014;725:18–22.
11. Reiner Ž, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–1818.
12. Sibbing D, Braun S, Jawansky S, et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost. 2008;99:121–126.
13. Tóth O, Calatzis A, Penz S, et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost. 2006;96:781–788.
14. Conover WJ. Practical Nonparametric Statistics. 3rd ed. New York, NY: John Wiley & Sons; 1999:204–216.
15. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505–1516.
16. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5:2429–2436.
17. Simon T, Verstuyft C, Mary-Krause M, et al; FAST-MI Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363–375.
18. Malmström R, Östergren J, Jørgensen L, et al. Influence of statin treatment on platelet inhibition by clopidogrel—a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment. J Intern Med. 2009;266:457–466.
19. Vinholt P, Poulsen TS, Korsholm L, et al. The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. Thromb Haemost. 2005;94:438–443.
20. Pelliccia F, Rosano G, Marazzi G, et al. Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy. Circ J. 2014;78:679–684.
21. Kreutz RP, Breall JA, Sinha A, et al. Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention. Clin Pharmacol. 2016;8:45–50.
22. Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med. 2004;164:2051–2057.